Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Protective effect of recombinant human glucagon-like peptide-1 (rhGLP-1) pretreatment in STZ-induced diabetic mice

Tools
- Tools
+ Tools

Wu, Ye-Lin, Huang, Jing, Liu, Jian, Jin, Ming-Fei, Gu, Mei, Hong, Yiguo and Wu, Zi-Rong (2011) Protective effect of recombinant human glucagon-like peptide-1 (rhGLP-1) pretreatment in STZ-induced diabetic mice. Journal of Peptide Science, Vol.17 (No.7). pp. 499-504. doi:10.1002/psc.1352

Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1002/psc.1352

Request Changes to record.

Abstract

Human glucagon-like peptide-1 (hGLP-1) and its mimetics have emerged as therapies for type 2 diabetes. However, clinical treatment of diabetes with hGLP-1 is ineffective because of rapid DPPIV-mediated hGLP-1 degradation in the circulation. In this study, we investigated the protective effect of recombinant human glucagon-like peptide-1 (rhGLP-1) treatment on STZ-induced diabeticmice. Mice were treated daily with rhGLP-1 (24 nmol/kg body weight) starting before or after STZ injection (40mg/kg body weight) to induce diabetes. Mice pretreated with rhGLP-1 before but not after STZ showed significantly reduced blood glucose levels (P < 0.05), increased oral glucose tolerance (area under the curve, 1740 +/- 71.18 vs 2416 +/- 205.6, P < 0.05). Furthermore, the bioproduct of lipid peroxidation, MDA, was reduced and SOD and GSH-PX activities were enhanced globally and in pancreas of mice that received rhGLP-1 pretreatment before STZ, when comparing with STZ-treated mice. Finally, STZ-induced pancreatic islet damage was rescued by rhGLP-1 pretreatment. Taken together, the results of this study demonstrate that rhGLP-1 pretreatment has a protective effect against STZ-induced diabetes in mice. These findings suggest that the GLP-1 pretreatment may be a new therapeutic strategy in the preventive and protective treatment during diabetes initiation and progression. Copyright (C) 2011 European Peptide Society and John Wiley & Sons, Ltd.

Item Type: Journal Article
Subjects: R Medicine > RB Pathology
R Medicine > RC Internal medicine
Divisions: Faculty of Science, Engineering and Medicine > Science > Life Sciences (2010- ) > Warwick HRI (2004-2010)
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Streptozotocin, Oxidative stress, Diabetes, Non-insulin-dependent diabetes, Glucagon-like peptide 1
Journal or Publication Title: Journal of Peptide Science
Publisher: John Wiley & Sons Ltd.
ISSN: 10752617
Official Date: July 2011
Dates:
DateEvent
July 2011Published
Volume: Vol.17
Number: No.7
Page Range: pp. 499-504
DOI: 10.1002/psc.1352
Status: Peer Reviewed
Publication Status: Published
Funder: National New Drug Development Program of China
Grant number: 2009ZX09102-253 (NNDDPC)

Data sourced from Thomson Reuters' Web of Knowledge

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us